Tectonic Therapeutic, Inc.
Financials
Valuation Metrics
Tectonic Therapeutic, Inc.'s Market Cap is $371M. At end of 2025 it was $382M. Ranked #2824 of 3,116 in US market (top 91%), #1248 of 1,472 on NASDAQ (top 85%), #225 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $371M | US#2,824/3,116 Sec#225/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-86M | US—/3,116 Sec—/265 |
| Total Assets | $237M | US#2,954/3,116 Sec#234/265 |
| Net Assets | $224M | US#2,628/3,116 Sec#176/265 |
| Employees | 60 | US#2,679/3,116 Sec#201/265 |
| Value | ||
| P/B | 1.66x | US#1,112/3,116 Sec#49/265 |
| FCF Yield | -19.55% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -38.32% | US#2,609/3,116 Sec#132/265 |
| ROA | -36.19% | US#2,920/3,116 Sec#178/265 |
| Financial Health | ||
| Debt Ratio | 5.89% | US#48/3,116 Sec#21/265 |
| Total Debt | $4M | US#2,902/3,116 Sec#218/265 |
| FCF | $-72M | US#2,579/3,116 Sec#127/265 |
| Cash | $227M | US#1,629/3,116 Sec#96/265 |
| Current Ratio | 22.29x | US#102/3,116 Sec#17/265 |
| Performance | ||
| 1Y Return | 3.89% | US#1,493/3,116 Sec#127/265 |
| 1M Return | -15.88% | US#2,660/3,116 Sec#205/265 |
| From 52W High | -52.04% | US#2,623/3,116 Sec#195/265 |
| 1Y MDD | -50.01% | US#2,289/3,116 Sec#151/265 |
| Trading | ||
| Volume | 170,872 shares | US#2,816/3,116 Sec#255/265 |
| Trading Value | $3M | US#2,819/3,116 Sec#231/265 |
| Per Share | ||
| EPS | $-4.39 | US—/3,116 Sec—/265 |
| BPS | $11.45 | US#1,746/3,116 Sec#64/265 |
Company Info
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.